ID   LNCaP-BicR
AC   CVCL_F0L7
RX   PubMed=28500234;
CC   Population: Caucasian.
CC   Characteristics: Resistant to 40 mmol/L of bicalutamide (PubMed=28500234).
CC   Selected for resistance to: ChEBI; CHEBI_3090; Bicalutamide.
CC   Sequence variation: Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1379 ! LNCaP clone FGC
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   PubMed=28500234; DOI=10.1158/1535-7163.MCT-16-0912; PMCID=PMC5544572;
RA   Liu, Cheng-Fei
RA   Armstrong, Cameron M.
RA   Lou, Wei
RA   Lombard, Alan P.
RA   Cucchiara, Vito
RA   Gu, Xin-Wei
RA   Yang, Joy C.
RA   Nadiminty, Nagalakshmi
RA   Pan, Chong-Xian
RA   Evans, Christopher P.
RA   Gao, Allen C.
RT   "Niclosamide and bicalutamide combination treatment overcomes
RT   enzalutamide- and bicalutamide-resistant prostate cancer.";
RL   Mol. Cancer Ther. 16:1521-1530(2017).
//